Borderline QuantiFERON results and the distinction between specific responses and test variability

Tuberculosis

Volumn 111, Issue , 2018, Pages 102-108

  Uzorka, Jonathan W ^a   Bossink, Ailko W J ^b   Franken, Willeke P J ^c   Thijsen, Steven F T ^d   Leyten, Eliane M S ^e   van Haeften, Alida C ^f   Doornenbal, Gert ^f   Boonstra, Peter ^f   Ottenhoff, Tom H M ^a   Arend, Sandra M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diakonessenhuis   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f Public Health Service of the city of Utrecht   (Netherlands)

Author keywords

Cut off; Elispot; Interferon gamma release tests; QuantiFERON; Tuberculosis

Indexed keywords

ISONIAZID; BIOLOGICAL MARKER; GAMMA INTERFERON; IFNG PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; YOUNG ADULT; ADOLESCENT; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; TIME FACTOR;

ADOLESCENT; BIOMARKERS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 85048227608     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2018.06.002     Document Type: Article

References (44)

1. Diel, R., Goletti, D., Ferrara, G., Bothamley, G., Cirillo, D., Kampmann, B., et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37:1 (2011), 88–99.
2. Brock, I., Munk, M.E., Kok-Jensen, A., Andersen, P., Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tubercul Lung Dis 5:5 (2001), 462–467.
3. Andrews, J.R., Nemes, E., Tameris, M., Landry, B.S., Mahomed, H., McClain, J.B., et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med 5:4 (2017), 282–290.
4. Joshi, M., Monson, T.P., Joshi, A., Woods, G.L., IFN-gamma release assay conversions and reversions. Challenges with serial testing in U.S. health care workers. Ann Am Thorac Soc 11:3 (2014), 296–302.
5. Metcalfe, J.Z., Cattamanchi, A., McCulloch, C.E., Lew, J.D., Ha, N.P., Graviss, E.A., Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 187:2 (2013), 206–211.
6. Herrera, V., Perry, S., Parsonnet, J., Banaei, N., Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 52:8 (2011), 1031–1037.
7. Nienhaus, A., Ringshausen, F.C., Costa, J.T., Schablon, A., Tripodi, D., IFN-gamma release assay versus tuberculin skin test for monitoring TB infection in healthcare workers. Expert Rev Anti Infect Ther 11:1 (2013), 37–48.
8. Ringshausen, F.C., Nienhaus, A., Schablon, A., Schlosser, S., Schultze-Werninghaus, G., Rohde, G., Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis, 10, 2010, 220.
9. Schablon, A., Nienhaus, A., Ringshausen, F.C., Preisser, A.M., Peters, C., Occupational screening for tuberculosis and the use of a borderline zone for interpretation of the IGRA in German healthcare workers. PLoS One, 9(12), 2014, e115322.
10. Slater, M.L., Welland, G., Pai, M., Parsonnet, J., Banaei, N., Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med 188:8 (2013), 1005–1010.
11. Tagmouti, S., Slater, M., Benedetti, A., Kik, S.V., Banaei, N., Cattamanchi, A., et al. Reproducibility of interferon gamma (IFN-gamma) release Assays. A systematic review. Ann Am Thorac Soc. 11:8 (2014), 1267–1276.
12. Diel, R., Loddenkemper, R., Nienhaus, A., Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142:1 (2012), 63–75.
13. Rangaka, M.X., Wilkinson, K.A., Glynn, J.R., Ling, D., Menzies, D., Mwansa-Kambafwile, J., et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12:1 (2012), 45–55.
14. Nemes, E., Rozot, V., Geldenhuys, H., Bilek, N., Mabwe, S., Abrahams, D., et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 196:5 (2017), 638–648.
15. Uzorka, J.W., Kroft, L.J.M., Bakker, J.A., van Zwet, E.W., Huisman, E., Knetsch-Prins, C., et al. Proof of concept that most borderline Quantiferon results are true antigen-specific responses. Eur Respir J, 50(5), 2017.
16. Bumbacea, D., Arend, S.M., Eyuboglu, F., Fishman, J.A., Goletti, D., Ison, M.G., et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 40:4 (2012), 990–1013.
17. Cattamanchi, A., Smith, R., Steingart, K.R., Metcalfe, J.Z., Date, A., Coleman, C., et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 56:3 (2011), 230–238.
18. Solovic, I., Sester, M., Gomez-Reino, J.J., Rieder, H.L., Ehlers, S., Milburn, H.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36:5 (2010), 1185–1206.
19. Arend, S.M., Thijsen, S.F., Leyten, E.M., Bouwman, J.J., Franken, W.P., Koster, B.F., et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 175:6 (2007), 618–627.
20. Franken, W.P., Arend, S.M., Thijsen, S.F., Bouwman, J.J., Koster, B.F., van Dissel, J.T., et al. Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts. Int J Tubercul Lung Dis 12:11 (2008), 1286–1294.
21. Leyten, E.M., Arend, S.M., Prins, C., Cobelens, F.G., Ottenhoff, T.H., van Dissel, J.T., Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 14:7 (2007), 880–885.
22. Arend, S.M., de, H.P., Leyten, E., Rosenkrands, I., Rigouts, L., Andersen, P., et al. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis 191:8 (2005), 1301–1310.
23. Arend, S.M., van Meijgaarden, K.E., de, B.K., de Palou, E.C., van, S.D., Ottenhoff, T.H., et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 186:12 (2002), 1797–1807.
24. Pai, M., Zwerling, A., Menzies, D., Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:3 (2008), 177–184.
25. Huebner, R.E., Schein, M.F., Bass, J.B. Jr., The tuberculin skin test. Clin Infect Dis 17:6 (1993), 968–975.
26. Pouchot, J., Grasland, A., Collet, C., Coste, J., Esdaile, J.M., Vinceneux, P., Reliability of tuberculin skin test measurement. Ann Intern Med 126:3 (1997), 210–214.
27. Farhat, M., Greenaway, C., Pai, M., Menzies, D., False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tubercul Lung Dis 10:11 (2006), 1192–1204.
28. Jonsson, J., Westman, A., Bruchfeld, J., Sturegard, E., Gaines, H., Schon, T., A borderline range for Quantiferon Gold In-Tube results. PLoS One, 12(11), 2017, e0187313.
29. Arend, S.M., de Haas, P., Leyten, E., Rosenkrands, I., Rigouts, L., Andersen, P., et al. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis 191:8 (2005), 1301–1310.
30. Arend, S.M., van Meijgaarden, K.E., de Boer, K., de Palou, E.C., van Soolingen, D., Ottenhoff, T.H., et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 186:12 (2002), 1797–1807.
31. Banaei, N., Gaur, R.L., Pai, M., Interferon gamma release assays for latent tuberculosis: what are the sources of variability?. J Clin Microbiol 54:4 (2016), 845–850.
32. Brown, J., Kumar, K., Reading, J., Harvey, J., Murthy, S., Capocci, S., et al. Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. Eur Respir J, 50(4), 2017.
33. Banaei, N., Pai, M., Detecting new Mycobacterium tuberculosis infection. Time for a more nuanced interpretation of QuantiFERON conversions. Am J Respir Crit Care Med 196:5 (2017), 546–547.
34. Clifford, V., Zufferey, C., Germano, S., Ryan, N., Leslie, D., Street, A., et al. The impact of anti-tuberculous antibiotics and corticosteroids on cytokine production in QuantiFERON-TB Gold in Tube assays. Tuberculosis 95:3 (2015), 343–349.
35. Shahidi, N., Fu, Y.T., Qian, H., Bressler, B., Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 18:11 (2012), 2034–2042.
36. Sester, M., van Leth, F., Bruchfeld, J., Bumbacea, D., Cirillo, D.M., Dilektasli, A.G., et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 190:10 (2014), 1168–1176.
37. Ruhwald, M., Aabye, M.G., Ravn, P., IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn 12:2 (2012), 175–187.
38. Zak, D.E., Penn-Nicholson, A., Scriba, T.J., Thompson, E., Suliman, S., Amon, L.M., et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387:10035 (2016), 2312–2322.
39. Goletti, D., Lee, M.R., Wang, J.Y., Walter, N., Ottenhoff, T.H.M., Update on tuberculosis biomarkers: from correlates of risk, to correlates of active disease and of cure from disease. Respirology 23:5 (2018), 455–466.
40. th 2018).
41. Petruccioli, E., Vanini, V., Chiacchio, T., Cuzzi, G., Cirillo, D.M., Palmieri, F., et al. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- gold in-tube assays in subjects with or without tuberculosis. Tuberculosis 106 (2017), 38–43.
42. Horne, D.J., Jones, B.E., Kamada, A., Fukushima, K., Winthrop, K.L., Siegel, S.A.R., et al. Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis. Int J Tubercul Lung Dis 22:6 (2018), 617–621.
43. Van Leth, F., Sester, M., Testing for LTBI: more of the same or a step forward?. Int J Tubercul Lung Dis, 22(6), 2018, 591.
44. Moon, H.W., Gaur, R.L., Tien, S.S., Spangler, M., Pai, M., Banaei, N., Evaluation of QuantiFERON(R)-TB gold-plus in healthcare workers in a low-incidence setting. J Clin Microbiol 55:6 (2017), 1650–1657 [Epub ahead of print].